Catheter ablation and mitral regurgitation: does valve treatment alter outcomes?

Atrial fibrillation (AF) and mitral regurgitation (MR) frequently coexist, creating a clinical problem in which atrial remodelling, raised filling pressures and valve disease reinforce one another. The central question is whether treating the valve first, alongside rhythm control, or after an unsuccessful ablation can improve freedom from AF and reduce complications. Learn more about Arrhythmia Burden In Pulmonary Arterial Hypertension Prognostic Significance.

For clinicians in Australia and the wider Asia-Pacific region, the decision is especially relevant as populations age and access to catheter ablation, cardiac imaging, surgical repair and transcatheter edge-to-edge repair expands. The answer depends on the type and severity of MR, the condition of the left atrium, ventricular function, symptoms, stroke risk and the durability of the proposed valve intervention.

Why mitral regurgitation changes the atrial substrate

MR exposes the left atrium to chronic volume overload. Over time, the atrium may enlarge, develop fibrosis and lose mechanical function, creating a substrate that supports both paroxysmal and persistent AF. Increased left-sided filling pressure can also promote pulmonary venous hypertension, exertional dyspnoea and recurrent hospital presentations.

The relationship is bidirectional. Rapid and irregular ventricular activation during AF can worsen leaflet coaptation through annular dilatation and altered ventricular mechanics. In some patients, restoring sinus rhythm reduces functional MR by improving atrial and ventricular coordination. In others, especially those with degenerative leaflet disease, AF is a marker of advanced valve pathology rather than its primary cause.

This distinction matters when interpreting ablation outcomes. A patient with moderate functional MR and a modestly enlarged atrium may experience reverse remodelling after rhythm control. Someone with severe primary MR, marked atrial enlargement and long-standing persistent AF has a more established substrate and may require structural treatment to change the trajectory.

What current evidence suggests about AF ablation

Catheter ablation can reduce symptomatic AF, improve exercise tolerance and limit arrhythmia burden in carefully selected patients with MR. Pulmonary vein isolation remains the procedural foundation, with additional lesions considered according to the arrhythmia pattern and substrate rather than applied routinely. Success is generally more likely when AF is paroxysmal and the left atrium is not substantially enlarged.

Observational studies have associated significant MR with higher recurrence after ablation, although the relationship is influenced by age, atrial size, ventricular function, AF duration and comorbidity. MR severity can also be measured inconsistently, particularly when loading conditions change between echocardiograms. These limitations make it difficult to attribute recurrence solely to the valve lesion.

The evidence base is therefore less definitive than for ablation in patients without important structural disease. Randomised comparisons of ablation alone, valve intervention followed by ablation, and combined strategies remain limited. Publications gathered in the journal’s collections can help clinicians follow evolving evidence across electrophysiology, imaging and structural heart intervention.

Valve treatment before rhythm intervention

Severe primary MR caused by prolapse, flail leaflet or other degenerative pathology generally requires assessment by a multidisciplinary valve team. Surgical repair is often preferred when a durable repair is feasible and operative risk is acceptable. Treating the valve can reduce atrial pressure and volume load, but it does not reliably reverse established atrial fibrosis or eliminate AF.

When AF is present at the time of mitral valve surgery, concomitant surgical ablation or left atrial appendage management may be considered within a carefully defined operative plan. The potential benefit must be balanced against procedure duration, pacemaker risk, bleeding and the patient’s overall surgical profile. A valve operation should not automatically be viewed as a substitute for a dedicated rhythm strategy.

Transcatheter edge-to-edge repair, commonly used for selected patients with severe MR and high surgical risk, may improve symptoms and haemodynamics. Whether it consistently improves long-term ablation success is uncertain. A reduction in regurgitant volume may create a more favourable environment for rhythm control, but the atrial substrate may remain abnormal after the valve has been treated.

Ablation before or after transcatheter repair

In secondary MR, the sequence is particularly difficult. Functional regurgitation may arise from left ventricular disease, atrial functional MR or a combination of both. Treating AF first can restore atrioventricular synchrony and reduce annular dilatation in selected patients, potentially avoiding or delaying an intervention. Conversely, severe MR with congestion may make an ablation less effective or less safe until haemodynamics improve.

A staged approach is often reasonable: optimise heart failure therapy, assess MR with high-quality transthoracic and transoesophageal echocardiography, and determine whether AF is a major driver of symptoms. If regurgitation remains severe despite medical therapy and rhythm control, valve intervention may be needed. If severe MR dominates the clinical picture, intervention may come first, followed by reassessment of AF burden.

In Australia, this pathway may differ between a metropolitan public hospital, a private cardiac centre and a regional service. Access to electrophysiology, cardiac surgery and transcatheter procedures is concentrated in cities such as Sydney, Melbourne, Brisbane and Perth, while patients from rural and remote areas may need coordinated travel, telehealth review and shared care after discharge.

Choosing endpoints that reflect patient benefit

Freedom from documented AF is an important endpoint, but it does not capture the whole value of treatment. Symptoms, functional capacity, left atrial volume, MR severity, heart failure admissions, stroke, bleeding, repeat procedures and quality of life should also be measured. Intermittent electrocardiography can miss asymptomatic episodes, so prolonged monitoring or an implanted device may be needed when accurate arrhythmia assessment is important.

A successful ablation does not automatically remove the need for anticoagulation. Antithrombotic therapy should be guided by validated stroke-risk assessment, the patient’s valve status and bleeding risk, rather than by apparent rhythm control alone. Mechanical valves and rheumatic mitral stenosis require particular attention because their anticoagulation requirements differ from those of non-valvular AF.

Australian prescribing and access also shape management. Direct oral anticoagulants are widely used for eligible patients and may be subsidised through the Pharmaceutical Benefits Scheme, while device follow-up and ablation pathways can involve different out-of-pocket costs across public and private systems. Shared decision-making should include travel, medication affordability, monitoring capacity and the practical demands of recovery.

Imaging and multidisciplinary assessment

Before ablation, echocardiography should establish MR mechanism, severity, leaflet anatomy, ventricular function, pulmonary pressure and atrial dimensions. Three-dimensional transoesophageal imaging can clarify prolapse, commissural disease and suitability for repair or edge-to-edge treatment. Cardiac magnetic resonance may help when echocardiographic grading is discordant or ventricular scar is suspected.

The electrophysiologist, imaging specialist, valve surgeon, interventional cardiologist, heart failure clinician and anaesthetist should agree on the dominant mechanism and treatment sequence. A patient with atrial functional MR may benefit from aggressive rhythm control, while a patient with flail posterior leaflet and severe symptoms may need prompt repair regardless of AF strategy.

The broader clinical context matters in Australia. Rheumatic heart disease remains disproportionately important in some Aboriginal and Torres Strait Islander communities, and recurrent rheumatic valve disease can produce a different risk profile from degenerative MR. Cultural safety, reliable follow-up and coordination with Aboriginal Community Controlled Health Services are essential when planning longitudinal anticoagulation, imaging and procedural care.

Research priorities and unresolved questions

Future studies should compare integrated treatment pathways rather than examining ablation and valve therapy in isolation. Important comparisons include ablation-first versus valve-first strategies, surgical repair with concomitant rhythm surgery versus staged catheter ablation, and transcatheter repair followed by ablation versus medical therapy. Trials should stratify patients by primary, ventricular functional and atrial functional MR.

Longer monitoring is also needed. Recurrence may occur after an initially successful procedure, and late valve deterioration can reactivate the arrhythmogenic substrate. Studies should report AF burden, not simply a single recurrence event, and should include outcomes that matter to patients, such as physical activity, breathlessness, hospitalisation and anticoagulant-related bleeding.

Research should also account for health-system realities. Australian registries could examine rural access, Indigenous health equity, waiting times, procedural volume and differences between public and private care. A recent discussion of arrhythmia burden and prognosis in pulmonary arterial hypertension illustrates why rhythm outcomes need to be interpreted alongside the underlying cardiovascular condition, rather than treated as an isolated electrical endpoint.

The available evidence supports an individualised strategy rather than a universal sequence. Valve intervention can improve haemodynamics and symptoms, but its effect on AF recurrence after catheter ablation depends on whether MR is the principal driver, a consequence of atrial disease or part of broader ventricular pathology. Careful phenotyping and joint decision-making remain more reliable than assuming that either procedure will solve both problems.

Clinicians and researchers can explore current evidence, educational material and themed collections through the Journal of Arrhythmia, and use these resources to support case review, multidisciplinary discussion and future investigation. Read the latest work, compare emerging approaches and contribute well-designed research that clarifies how valve treatment and rhythm control should be combined in patients with AF and MR.